Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Dexamethasone
Doxorubicin
Humans
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Propensity Score
Rituximab
Vincristine

authors with profiles

ISSA F KHOURI
RICHARD E CHAMPLIN
PARTOW KEBRIAEI
MARINA KONOPLEVA
GUILLERMO GARCIA-MANERO
JOSEPH KHOURY
JEFFREY L JORGENSEN
ELIAS JOSEPH JABBOUR
NITIN JAIN
KOICHI TAKAHASHI
HAGOP M KANTARJIAN